Dr. Donald M. Cannon, MD

Dr. Cannon practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Cannon's NPI, 1780820050, was assigned on December 16, 2008. Dr. Cannon graduated from JS Weill Medical College, Cornell University in 2008. Dr. Cannon holds Utah license 9876845-1205.

Dr. Cannon's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Cannon's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Cannon is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Cannon to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cannon practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Cannon's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Cannon's licenses on file in 2 states: Utah and Idaho.

CMS data shows 1,344 Medicare services from Dr. Cannon across 19 procedure codes in 2024, for 270 Medicare patients. Medicare paid $102,845 for them.

CMS counts 270 Medicare patients who saw Dr. Cannon in 2024. The largest group is 65 to 74, with 151 patients. 72% of them have high blood pressure, and 57% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cannon's median patient age at 70, with 47% women.

In 2024, Dr. Cannon wrote 173 Medicare Part D claims for 69 patients. 98% of them were for generic drugs. CMS names the drug for 120 of them, across 5 drugs with 11 or more claims each, at $1,563 in total drug cost. In 2023, CMS named 61 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Cannon for performance year 2024, reported as part of a group. Dr. Cannon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cannon as offering telehealth.

Dmand AI links 33 papers to Dr. Cannon, published from 2011 to 2025. 2022 was the busiest year, with 4. The most frequent topics are Carcinoma, Squamous Cell, Brachytherapy and Head and Neck Neoplasms. Dr. Cannon has published most often in Clin Genitourin Cancer. Dr. Cannon's most frequent co-authors are Lindsay Morgan Burt, MD, Dennis C. Shrieve, MD and Christopher Ryan Weil, MD.

Dmand AI links Dr. Cannon to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Brain Neoplasms and Central Nervous System Neoplasms.

CMS Open Payments shows 5 general payments to Dr. Cannon from 3 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Telix Pharmaceuticals paid the most, $119.

Dr. Cannon graduated from JS Weill Medical College, Cornell University in 2008.